DCGI nod for intranasal booster dose trials

January 28, 2022 13:53

Drugs Controller General of India (DCGI) gives permission to Bharat Biotech for intranasal booster dose trials. The trials will be done at 9 different sites.

The Hyderabad-based manufacturer has proposed the booster dose for those who have been already been innoculated against COVID with Covishield and Covaxin vaccines.

Bharat Biotech aims to conduct clinical trials on 5,000 subjects (50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin).

The interval between the second dose and booster dose will be six months, sources have told. According to the sources, India is expected to get an Intranasal booster vaccine in March, after timely conduction of trials.

« Back to LIVE

TOP STORIES

Rampaging SRH eye another run-fest against bottom-placed RCB

Sunrisers Hyderabad will look to unleash their brute batting power on struggling Royal Challengers Bengaluru when the two teams face off in their return-leg fixture of the IPL in Hyderabad on Thursday.

Priya's Simple, Stylish Avatars

When in doubt, she embraces a wardrobe that's part cool, part modern.

SC seeks clarification from EC on functioning of EVMs

The court said it needs clarification on certain aspects as there was some confusion in answers given by the EC in its 'frequently asked questions' (FAQs) on EVMs.

CSK Vs LSG: Who Took The Best Catch? Vote!

K L Rahul's diving catch was one of the highlights of LSG's fine showing against CSK.

Recipe: Mayur's Khawa Poli

C'mon have a midweek sweet surprise...